284 related articles for article (PubMed ID: 12923074)
1. Mitochondria-targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants.
Jauslin ML; Meier T; Smith RA; Murphy MP
FASEB J; 2003 Oct; 17(13):1972-4. PubMed ID: 12923074
[TBL] [Abstract][Full Text] [Related]
2. Protective effects of Fe-Aox29, a novel antioxidant derived from a molecular combination of Idebenone and vitamin E, in immortalized fibroblasts and fibroblasts from patients with Friedreich Ataxia.
Jauslin ML; Vertuani S; Durini E; Buzzoni L; Ciliberti N; Verdecchia S; Palozza P; Meier T; Manfredini S
Mol Cell Biochem; 2007 Aug; 302(1-2):79-85. PubMed ID: 17476463
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of PGC-1α and metabolic sensors suggest age-dependent induction of mitochondrial biogenesis in Friedreich ataxia fibroblasts.
García-Giménez JL; Gimeno A; Gonzalez-Cabo P; Dasí F; Bolinches-Amorós A; Mollá B; Palau F; Pallardó FV
PLoS One; 2011; 6(6):e20666. PubMed ID: 21687738
[TBL] [Abstract][Full Text] [Related]
4. Fine-tuning the hydrophobicity of a mitochondria-targeted antioxidant.
Asin-Cayuela J; Manas AR; James AM; Smith RA; Murphy MP
FEBS Lett; 2004 Jul; 571(1-3):9-16. PubMed ID: 15280009
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial dysfunction in Friedreich's ataxia: from pathogenesis to treatment perspectives.
Lodi R; Rajagopalan B; Bradley JL; Taylor DJ; Crilley JG; Hart PE; Blamire AM; Manners D; Styles P; Schapira AH; Cooper JM
Free Radic Res; 2002 Apr; 36(4):461-6. PubMed ID: 12069111
[TBL] [Abstract][Full Text] [Related]
6. Friedreich's ataxia: from disease mechanisms to therapeutic interventions.
Lodi R; Tonon C; Calabrese V; Schapira AH
Antioxid Redox Signal; 2006; 8(3-4):438-43. PubMed ID: 16677089
[TBL] [Abstract][Full Text] [Related]
7. Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties.
Kelso GF; Porteous CM; Coulter CV; Hughes G; Porteous WK; Ledgerwood EC; Smith RA; Murphy MP
J Biol Chem; 2001 Feb; 276(7):4588-96. PubMed ID: 11092892
[TBL] [Abstract][Full Text] [Related]
8. Deferiprone and idebenone rescue frataxin depletion phenotypes in a Drosophila model of Friedreich's ataxia.
Soriano S; Llorens JV; Blanco-Sobero L; Gutiérrez L; Calap-Quintana P; Morales MP; Moltó MD; Martínez-Sebastián MJ
Gene; 2013 Jun; 521(2):274-81. PubMed ID: 23542074
[TBL] [Abstract][Full Text] [Related]
9. Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury.
Adlam VJ; Harrison JC; Porteous CM; James AM; Smith RA; Murphy MP; Sammut IA
FASEB J; 2005 Jul; 19(9):1088-95. PubMed ID: 15985532
[TBL] [Abstract][Full Text] [Related]
10. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up.
Hart PE; Lodi R; Rajagopalan B; Bradley JL; Crilley JG; Turner C; Blamire AM; Manners D; Styles P; Schapira AH; Cooper JM
Arch Neurol; 2005 Apr; 62(4):621-6. PubMed ID: 15824263
[TBL] [Abstract][Full Text] [Related]
11. Targeting lipid peroxidation and mitochondrial imbalance in Friedreich's ataxia.
Abeti R; Uzun E; Renganathan I; Honda T; Pook MA; Giunti P
Pharmacol Res; 2015 Sep; 99():344-50. PubMed ID: 26141703
[TBL] [Abstract][Full Text] [Related]
12. MitoQ--a mitochondria-targeted antioxidant.
Tauskela JS
IDrugs; 2007 Jun; 10(6):399-412. PubMed ID: 17642004
[TBL] [Abstract][Full Text] [Related]
13. Efficient attenuation of Friedreich's ataxia (FRDA) cardiomyopathy by modulation of iron homeostasis-human induced pluripotent stem cell (hiPSC) as a drug screening platform for FRDA.
Lee YK; Lau YM; Ng KM; Lai WH; Ho SL; Tse HF; Siu CW; Ho PW
Int J Cardiol; 2016 Jan; 203():964-71. PubMed ID: 26625322
[TBL] [Abstract][Full Text] [Related]
14. Friedreich's Ataxia: disease mechanisms, antioxidant and Coenzyme Q10 therapy.
Cooper JM; Schapira AH
Biofactors; 2003; 18(1-4):163-71. PubMed ID: 14695932
[TBL] [Abstract][Full Text] [Related]
15. The mitochondria targeted antioxidant MitoQ protects against fluoroquinolone-induced oxidative stress and mitochondrial membrane damage in human Achilles tendon cells.
Lowes DA; Wallace C; Murphy MP; Webster NR; Galley HF
Free Radic Res; 2009 Apr; 43(4):323-8. PubMed ID: 19235604
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial impairments contribute to Spinocerebellar ataxia type 1 progression and can be ameliorated by the mitochondria-targeted antioxidant MitoQ.
Stucki DM; Ruegsegger C; Steiner S; Radecke J; Murphy MP; Zuber B; Saxena S
Free Radic Biol Med; 2016 Aug; 97():427-440. PubMed ID: 27394174
[TBL] [Abstract][Full Text] [Related]
17. A cellular model for Friedreich Ataxia reveals small-molecule glutathione peroxidase mimetics as novel treatment strategy.
Jauslin ML; Wirth T; Meier T; Schoumacher F
Hum Mol Genet; 2002 Nov; 11(24):3055-63. PubMed ID: 12417527
[TBL] [Abstract][Full Text] [Related]
18. Protective efficacy of mitochondrial targeted antioxidant MitoQ against dichlorvos induced oxidative stress and cell death in rat brain.
Wani WY; Gudup S; Sunkaria A; Bal A; Singh PP; Kandimalla RJ; Sharma DR; Gill KD
Neuropharmacology; 2011 Dec; 61(8):1193-201. PubMed ID: 21784090
[TBL] [Abstract][Full Text] [Related]
19. The mitochondria-targeted antioxidant MitoQ protects against organ damage in a lipopolysaccharide-peptidoglycan model of sepsis.
Lowes DA; Thottakam BM; Webster NR; Murphy MP; Galley HF
Free Radic Biol Med; 2008 Dec; 45(11):1559-65. PubMed ID: 18845241
[TBL] [Abstract][Full Text] [Related]
20. The mitochondria-targeted antioxidant MitoQ extends lifespan and improves healthspan of a transgenic Caenorhabditis elegans model of Alzheimer disease.
Ng LF; Gruber J; Cheah IK; Goo CK; Cheong WF; Shui G; Sit KP; Wenk MR; Halliwell B
Free Radic Biol Med; 2014 Jun; 71():390-401. PubMed ID: 24637264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
